UK Markets closed

4D pharma plc (DDDD.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
136.00-10.00 (-6.85%)
At close: 4:35PM GMT

4D pharma plc

9 Bond Court
Fifth Floor
Leeds LS1 2JZ
United Kingdom

http://www.4dpharmaplc.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees127

Key executives

NameTitlePayExercisedYear born
Mr. Duncan Joseph PeytonCEO & Exec. Director102kN/A1970
Dr. Alexander James StevensonChief Scientific Officer & Exec. Director102kN/A1972
Mr. Stephen DunbarFin. DirectorN/AN/AN/A
Fay WestonHead of Investor RelationsN/AN/AN/A
Mr. Laurence DaleGen. Counsel & Company Sec.N/AN/AN/A
Dr. John D. WeinbergChief Medical OfficerN/AN/A1967
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease. It also develops immuno-oncology products comprising MRx0518, MRx0573, and MRx1299 for solid tumors, and MRx0518 for pancreatic cancer; respiratory products, such as MRx-4DP0004 for asthma and COVID-19; central nervous system products, including MRx0005 and MRx0029 for neurodegeneration; and platform products comprising vaccines and autoimmune. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumours. The company was formerly known as Schosween 18 Limited. 4D pharma plc was founded in 2014 and is headquartered in Leeds, the United Kingdom.

Corporate governance

4D pharma plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.